Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
announced Wednesday, the latest findings suggesting popular weight loss drugs have the potential to treat conditions other than obesity or type 2 diabetes. Participants across two studies lost about 20% of their body weight while using the drug. Participants across two studies who used Zepbound experienced fewer AHI events—when a person partially or fully stops breathing while asleep—per hour compared to a placebo after 52 weeks, Eli Lilly said All participants were adults with obesity and moderate to severe sleep apnea. In the first study, Zepbound resulted in an average reduction of 27.4 AHI events per hour among participants who did not use a positive airway pressure (PAP) machine, compared to 4.8 events per hour among participants who took a placebo, the company said. During a second study in which participants used PAP machines, Zepbound resulted in an average reduction of 30.4 events per hour compared to 6 events per hour for the placebo group. Eli Lilly said Zepboun
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows [Yahoo! Finance]Yahoo! Finance
- No belt-tightening for obesity meds with market set to swell 10-fold [Yahoo! Finance]Yahoo! Finance
- Siri's First Head of Product and Design Launches Proemial, a New AI Startup Combating Misinformation [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website